Clinical trial · Interventional
Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Ovarian Carcinoma
NCT02487693CI-TRIAL-00021046active not recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine whether combining of radiofrequency ablation (RFA) and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with ovarian carcinoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Carcinoma | Ovarian Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cytokine-induced killer cells | Biological | — | UNRESOLVED |
| Radiofrequency ablation | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- NO_INTERVENTION
- label
- RFA alone
- description
- Patients undergo radiofrequency ablation alone.
- type
- EXPERIMENTAL
- label
- RFA+CIK
- description
- Autologous cytokine-induced killer cells were transfer via venous one week after RFA Interventions
- interventionNames
- Procedure: Radiofrequency ablation
- Biological: Cytokine-induced killer cells
Primary outcomes (1)
- measure
- Recurrence-free survival
- timeFrame
- 1 year
- description
- Recurrence-free survival (RFS) was defined as the time from the date of RFA to the date of recurrence or the date of the last follow-up.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 30 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: 1. patients diagnosed with FIGO stage II ovarian carcinoma; 2. cytoreductive surgery performed and 6 courses of platinum-based chemotherapy completed; 3. medical records maintain comprehensive data on treatment and follow-up; 4. no history of previous malignancies. Exclusion Criteria: 1. neoadjuvant chemotherapy applied; 2. less than 6 courses of chemotherapy or more than 6 courses of chemotherapy completed; 3. medical records maintain incomplete data on treatment or follow-up; 4. history of previous malignancy.
References
Publications (0)
Data not yet available
No reference posted for this study.